SEARCH

SEARCH BY CITATION

References

  • 1
    Abbott JD, Ahmed HN, Vlachos HA, et al. Comparison of outcome in patients with ST-elevation versus non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol. 2007;100:190195.
  • 2
    Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2003;24:2866.
  • 3
    Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Associations Task Force on Practice Guidelines. Circulation. 2004;110:e82e293.
  • 4
    Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:15981660.
  • 5
    Gibler WB, Cannon CP, Blomkalns AL, et al. Practical implementation of the guidelines for unstable angina/Non-ST-elevation myocardial infarction in the emergency department. Circulation. 2005;111:26992710.
  • 6
    Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:10011009.
  • 7
    ISIS-2 Collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2:349360.
  • 8
    Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163:20062010.
  • 9
    The LIPID study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:13491357.
  • 10
    Spencer FA, Santopinto JJ, Gore JM, et al. Impact of aspirin on presentation and hospital outcomes in patients with acute coronary syndromes. Am J Cardiol. 2002;90:10561061.
  • 11
    Spencer FA, Allegrone J, Goldberg J, et al. Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. Ann Intern Med. 2004;140:857866.
  • 12
    National Kidney Foundation. Kidney disease outcome quality initiative. Clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1S266.
  • 13
    Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:12851295.
  • 14
    Ethier J, Bragg-Gresham JL, Piera L, et al. Aspirin prescription and outcomes in hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2007;50:602611.
  • 15
    Strippoli GFM, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomized controlled trials. BMJ. 2008;336:645651.
  • 16
    Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461470.
  • 17
    Col NF, Yarzbski J, Gore JM, et al. Does aspirin consumption affect the presentation or severity of acute myocardial infarction? Arch Intern Med. 1995;155:13861389.
  • 18
    Borzak S, Cannon CP, Kraft PL, et al. Effects of prior aspirin and anti-ischemic therapy on outcome of patients with unstable angina. Am J Cardiol. 1998;81:678681.
  • 19
    Montalescot G, Dallongeville J, Van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition. Eur Heart J. 2007;28:14091417.
  • 20
    Mc Cullough PA. Beyond serum creatinina: defining the patient with renal insufficiency and why? Rev Cardiovasc Med. 2003;4(suppl 1):S2S6.